This trial is active, not recruiting.

Conditions myopathy, muscular weakness, respiratory insufficiency
Treatment bilevel pressure ventilator
Phase phase 3
Sponsor Assistance Publique - Hôpitaux de Paris
Collaborator Association Française contre les Myopathies (AFM), Paris
Start date October 2010
End date July 2018
Trial size 77 participants
Trial identifier NCT01225614, 2009-A01023-54 (IDRCB), P081221


This is a multicenter randomized controlled open labeled study testing efficacy and tolerance of early launching of night non invasive ventilation in patients with myotonic dystrophy type 1(DM1). The object of this project is to estimate the effects of the early introduction of non invasive ventilation on the arisen of complication (non expected hospitalization, tracheostomy even death) with regard to a simple respiratory follow-up in patients affected by myotonic dystrophy.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification safety/efficacy study
Intervention model parallel assignment
Masking open label
Primary purpose treatment
bilevel pressure ventilator
Nocturnal home ventilation
(Active Comparator)
Standard care and ventilation if occurrence of absolute criteria of ventilation (cf infra).
bilevel pressure ventilator
Nocturnal home ventilation

Primary Outcomes

Rate of patients having a complication (number of non expected hospitalization or death) at 5 years.
time frame: 5 YEARS

Secondary Outcomes

Distribution of survival between the randomisation at 5 years
time frame: 5 YEARS
Number of patients having a formal indication of ventilation
time frame: 5 YEARS
Number of tracheostomized patients at 5 years
time frame: 5 YEARS
Number of non expected hospitalizations at 5 years
time frame: 5 YEARS
Observance of the ventilation defined by an average minimal use of 4 am by 12:00 pm .
time frame: 5 YEARS
Degree of respiratory and sleep impairment at 5 years
time frame: 5 YEARS
Quality of life SF36, scales of depression
time frame: 5 YEARS

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: - Man or woman of age ≥ 18 years - Preliminary medical examination - Enlightened and written consent - Genetically proved Steinert disease 1. Presenting at least one of the following 3 criteria - A hypercapnia: PaCO2 > 45 mmHg or - A night-desaturation: SaO2 < 88 % more than consecutive 5 minutes or - Apnea syndrome with significant sleep:index of apnea / hypopnea> a 30 / hour 2. And with presence of at least a clinical sign: dyspnoea, orthopnea, headaches, asthenia, diurnal sleepiness, or any other sign suggestive of disturbance of the sleep or of respiratory dysfunction Exclusion Criteria: - Age inferior to 18 - Regime of legal protection - Pregnancy - Absolute indication for ventilation: clinical signs (dyspnoea, orthopnea, headaches, asthenia, diurnal sleepiness), AND PaCO2 > 60 mmHg, AND night-desaturation < 88 % AND one CV < 50 % of the theoretical or the PIMAX < 60 cm H2O - Acute respiratory failure - Already ventilated patient - Patient under oxygen - Not (beneficiary to a regime of Social Security or legal successor)

Additional Information

Official title Study of Efficacy and Tolerance of Early Launching of Nocturnal Non Invasive Ventilation in Adults With Myotonic Dystrophy Type 1(DM1)
Principal investigator DAVID ORLIKOWSKI, MD, PhD
Description DM1 is the most frequent genetic myopathy in the adult. Actually there is no curative treatment, and symptomatic cares are essentials. The respiratory impairment is the main cause of morbid-mortality at these patients. The median of survival of the patients affected by DM1 with respiratory failure is of 59 years. Mechanisms of disease are complex implying a central and a direct impairment of respiratory muscles. These patients can present an alveolar hypoventilation, notably during night, not correlated to the muscular weakness. These patients often present a cognitive impairment complicating the interpretation of the clinical symptoms and their compliance to treatments. International recommendations for launching mechanical ventilation in neuromuscular diseases are the presence: 1) at least a clinical sign of alveolar hypoventilation, and one of the following criteria 2) diurnal hypercapnia (> 45 mmHg), 3) restrictive syndrome (vital capacity < 50 % and\or maximal inspiratory pressure < 60 cmH20), 4) the existence of a oxygen night-desaturation (SaO2 < 88 %) of more than 5 minutes. However, a Cochrane meta analyzes underline the absence of randomised study estimating the profit risk in the long term of the night-mechanical ventilation for progressive myopathies such as the DM1. The validity of these criteria and the effect of the ventilation on the survival and the complications were never estimated in DM1. On a retrospective series, the compliance is inferior and the observance is only 20 % a year and the incidence of the complications (death or resort to a tracheostomy) was 6 times as important in non observant patients. Objective (s) of the clinical study To estimate the efficiency and the tolerance of long term night-non invasive mechanical ventilation in patients affected by DM1. Main judgment criteria: Mortality and non programmed hospitalization. Experimental plan: Multicenter, national, randomized, controlled, study on 2 parallel groups. The subjects presenting a theoretical indication following consensual criteria of ventilation will be randomized either for a start up of ventilation or for an annual monitoring. Hypothesis: Early starting of non invasive ventilation allows a reduction of 20 % of the mortality or the number of non-programmed hospitalization compared to the control group for which the rate would be 40 %.
Trial information was received from ClinicalTrials.gov and was last updated in February 2016.
Information provided to ClinicalTrials.gov by Assistance Publique - Hôpitaux de Paris.